• Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.40
  • Forecasted Upside: 328.57%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.96
▼ -0.01 (-0.51%)

This chart shows the closing price for ERAS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Erasca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ERAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ERAS

Analyst Price Target is $8.40
▲ +328.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Erasca in the last 3 months. The average price target is $8.40, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 328.57% upside from the last price of $1.96.

This chart shows the closing price for ERAS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Erasca. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2024Bank of AmericaDowngradeBuy ➝ Neutral$11.00 ➝ $6.00Low
11/29/2023MizuhoLower TargetBuy ➝ Buy$8.00 ➝ $7.00Low
11/28/2023HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $8.00Low
10/11/2023HC WainwrightInitiated CoverageBuy$10.00Low
6/6/2023Evercore ISILower Target$20.00 ➝ $11.00Low
6/6/2023MizuhoLower Target$9.00 ➝ $8.00Low
3/29/2023MizuhoInitiated CoverageBuy$9.00Low
2/24/2023The Goldman Sachs GroupInitiated CoverageBuy$10.00Low
2/3/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$15.00Low
1/3/2022GuggenheimLower Target$25.00 ➝ $20.00High
8/10/2021Evercore ISIInitiated CoverageOutperformHigh
8/10/2021JPMorgan Chase & Co.Initiated CoverageOverweight$28.00High
8/10/2021GuggenheimInitiated CoverageBuy$25.00High
8/10/2021Morgan StanleyInitiated CoverageEqual Weight$25.00High
8/10/2021Bank of AmericaInitiated CoverageBuy$28.00High
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/21/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Erasca logo
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.96
Low: $1.96
High: $1.96

50 Day Range

MA: $1.90
Low: $1.67
High: $2.20

52 Week Range

Now: $1.96
Low: $1.51
High: $3.88

Volume

104 shs

Average Volume

635,460 shs

Market Capitalization

$296.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Erasca?

The following sell-side analysts have issued research reports on Erasca in the last year: Bank of America Co., Evercore ISI, HC Wainwright, Mizuho, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ERAS.

What is the current price target for Erasca?

5 Wall Street analysts have set twelve-month price targets for Erasca in the last year. Their average twelve-month price target is $8.40, suggesting a possible upside of 328.6%. Evercore ISI has the highest price target set, predicting ERAS will reach $11.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $6.00 for Erasca in the next year.
View the latest price targets for ERAS.

What is the current consensus analyst rating for Erasca?

Erasca currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ERAS.

What other companies compete with Erasca?

How do I contact Erasca's investor relations team?

The company's listed phone number is 858-465-6511 and its investor relations email address is [email protected]. The official website for Erasca is www.erasca.com. Learn More about contacing Erasca investor relations.